Get the content you want anytime you want.
REGISTER NOW | SIGN IN
The Best Infectious Disease News Delivered Weekly

The Contagion® C. Difficile specialty page provides c. difficile-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

C. DIFFICILE VIDEOS - Page 2

How Do <i>C. diff</i>-Associated Costs Compare With Other HAIs?
Glenn Tillotson, PhD, FIDSA, explains how costs associated with Clostridium difficile compare with other problematic health care-associated infections.
Immunization Coverage: Why It's Harder to Cover Adults
Richard Haupt, MD, MPH, explains why it’s harder to cover adults rather than children when it comes to vaccination.  
Study Finds Mattress Covers Cut Hospital CDI Rates in Half
Edmond Hooker, MD, DrPH, discusses a study that assessed the use of mattress covers in hospitals to cut down on CDI rates.
Fidaxomicin in the Treatment of <i>Clostridium difficile</i> Infections
Erik Dubberke, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, compare the use of fidaxomicin against standard therapy options, such as vancomycin, for the treatment of Clostridium difficile, suggesting that fidaxomicin may reduce a patient’s risk of recurrence.
How Does Ridinilazole Affect the Gut Microbiome?
Dr. Richard Vickers, explains how ridinilazole affected the gut microbiome in participants of a phase 2 study.
 
Factors That Impact <i>C. difficile</i> Infection Recurrence
Following a discussion on how to monitor patients with Clostridium difficile for a response to treatment, Lawrence J. Brandt, MD; Erik Dubberke, MD; Dale N. Gerding, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, remark on the risk of recurrence and management of patients’ post therapy and how to proceed if recurrence occurs.
Contaminated Hospital Mattresses Act as Vector for Drug-Resistant Infections
Edmond Hooker, MD, DrPH, discusses how contaminated hospital mattresses act as a vector for spreading drug-resistant infections.
Ridinilazole Shows Superior Efficacy for Treatment of <i>C. diff</i> in Phase 2 Study
Dr. Richard Vickers, discusses how ridinilazole showed superior efficacy for the treatment of C. diff when compared with vancomycin in a phase 2 study.
FEATURED
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.